TRPM2 and neoplasm: Previously, depletion of TRPM2 with CRISPR technology or inhibition with a dominant negative isoform was found to significantly impair neuroblastoma cell survival and tumor growth through modulation of mitochondrial function, mitochondrial calcium uptake, ROS production, and cellular bioenergetics (5, 8).